The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Bioavailability Enhancement Technologies and Services Market, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    January 2020

  • Pages
    274

  • View Count
    3359

Example Insights

Bioavailability Enhancement - List of Companies Bioavailability Enhancement - Market Landscape Bioavailability Enhancement - Benchmark Analysis
Bioavailability Enhancement - Partnerships & Collaborations Bioavailability Enhancement - Demand Analysis Bioavailability Enhancement - Market Forecast
Bioavailability Enhancement - Opportunity Analysis    

 

Overview

Low bioavailability is one of the primary concerns associated with marketed drugs; in fact, various studies indicate that around 40% of available drugs are poorly bioavailable / soluble. As the drug developers shift their focus towards development of lipophilic drug compounds, the issue with aqueous solubility / bioavailability of the drugs is likely to increase further. It is estimated that around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low solubility / permeability. Given that a large number of drugs fail to reach the market due to poor bioavailability, the industry is looking for various tools / methods to mitigate this challenge. Moreover, as many companies seek to re-formulate existing product candidates that exhibit poor bioavailability (via the 505(b)(2) pathway), the demand for novel bioavailability enhancement methods has grown significantly.

To cater to this increasing demand, several contract manufacturers and technology providers have emerged in this domain. With more than 150 companies offering technologies / services for bioavailability enhancement, the market is highly fragmented; having said that, several mergers / acquisitions have also taken place as stakeholders strive to broaden their respective service portfolios. A number of players have developed novel, state-of-the art technologies to maintain a competitive edge in this rapidly emerging market. As drug developers continue to evaluate novel drug targets and classes, the bioavailability enhancement domain is expected to grow at a steady pace. In fact, since 2010, more than 4,000 articles, evaluating various bioavailability enhancement technologies have been published across several reputed journals. In addition, more than 6,000 patents have been filed post 2010, providing a significant scientific push to the development of novel approaches.

Scope of the Report

The ‘Bioavailability Enhancement Technologies and Services Market, 2020-2030’ report provides a comprehensive study on the current scenario of technologies and contract services related to bioavailability enhancement. The study features an elaborate discussion on the novel approaches adopted by different players offering solutions for altering the bioavailability of various drugs. Amongst other elements, the report features:

  • An overview of the current market landscape, featuring a comprehensive list of over 150 active contract services / technology providers, and a detailed analysis based on a number of parameters, such as geographical location of the company, approach adopted for bioavailability enhancement (size reduction, solid dispersion, lipid based methods and other novel approaches), type of dosage forms (solid, liquid, semi-solid, others), route of drug administration (oral, injectable, inhalation and topical).
  • Elaborate profiles of key players (identified on the basis of the breadth of their respective service portfolios) that are offering bioavailability enhancement services. Each profile features an overview of the company, its financial performance (if available), services portfolio, recent collaborations and the future outlook of the company.
  • An analysis of ongoing clinical studies evaluating the bioavailability of various drug compounds. The chapter features a comprehensive view on the focus areas of these clinical studies, highlighting the key players involved.
  • A review of the published scientific literature on bioavailability enhancement technologies, highlighting the heightened research activity and the focus areas of research groups across different types of bioavailability enhancement technologies.
  • A detailed analysis of over 6,000 patents that have been filed related to bioavailability enhancement technologies. The study presents a high-level view on the valuation of these patents and also highlights the emerging trends related to the innovation in this domain.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements, mergers and acquisitions, co-service agreements, manufacturing and service agreements, and other relevant types of deals.
  • A comprehensive benchmark analysis, highlighting the key focus areas of small, mid-sized and large sized companies; the benchmark analysis provides a means to compare the existing capabilities within respective peer groups and help industry stakeholders identify ways to achieve a competitive edge over contemporary players.
  • A detailed estimation of the likely demand for bioavailability enhancement technologies / services. It provides a comprehensive view, in terms, of the annual number of projects, that are likely to require bioavailability enhancement over the period 2018-2030.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as likely number of candidates in BCS II and IV, likely adoption rates of bioavailability enhancement approaches, expected trend in outsourcing and likely pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. To account for the uncertainties associated with the expected future demand and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2  provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the bioavailability enhancement technologies and services market in the short-mid and long term.

Chapter 3  is a general introduction to bioavailability. In this section, we have discussed, in detail, the concept of bioavailability and the current problems associated with bioavailability across various drug compounds. The chapter also features a detailed discussion on the current approaches being used for bioavailability enhancement.

Chapter 4  provides a comprehensive review of the global landscape of bioavailability enhancement technologies and service providers. It includes information related to over 150 companies that are currently operating in this domain. It features an in-depth market review, including a study of the regional distribution of players, analysis by company size and year of establishment, approach adopted for bioavailability enhancement, type of drug dosage form, route of administration, and the location of the company.

Chapter 5  features detailed profiles of some of the key players that are active in this domain and offer a wide range of services. Each profile presents an overview of the company, its financial information ( if available ), details related to its service(s) portfolio, recent developments (acquisitions / mergers, collaborations and expansions) and a comprehensive future outlook.

Chapter 6  presents a benchmark analysis of all the players engaged in this domain. It highlights the capabilities of these companies in terms of their expertise across bioavailability enhancement. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to become more competitive in the industry.

Chapter 7  features an elaborate discussion on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements prevalent in this domain. In addition, we have highlighted the key players, on the basis of the number of collaborations and also discussed the expansion of services (via acquisitions / mergers) by key players.

Chapter 8  provides a comprehensive publication analysis, highlighting the recent trends in published literature related to bioavailability enhancement technologies. It presents a relative comparison of key technologies, on the basis of the trend in number of publications (CAGR) and the impact factors of the journals wherein these articles were published.

Chapter 9  provides detailed analysis of the patents that have recently been filed related to bioavailability enhancement technologies. The study also highlights the upcoming trends in innovation in this domain. In addition, it presents a high-level view on the valuation of these patents

Chapter 10  features an overview of the various ongoing clinical studies that are evaluating the bioavailability of various drug candidates that are currently under development. The chapter features a comprehensive view on the focus areas of these clinical studies, highlighting the key players involved as well.

Chapter 11  presents a detailed estimation of the likely demand for bioavailability enhancement technologies / services. It provides a comprehensive view in terms of the annual number of projects that are likely to require bioavailability enhancement in the period 2020-2030.

Chapter 12  provides a comprehensive market forecast analysis, highlighting the future potential of contract services for bioavailability enhancement till the year 2030. It features the likely distribution of the market based on [A] approach used for bioavailability enhancement (solid dispersion, size reduction, lipid-based approaches, and other approaches), [B] region (North America, Europe, Asia-Pacific and rest of the world), and [C] opportunity from drugs across different BCS classifications (BCS II and BCS IV).

Chapter 13  is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters. It also provides a brief overview of some of the upcoming future trends, which, we believe, are likely to influence the growth of this market in the foreseen future.

Chapter 14  is a collection of transcripts of the discussions by various stakeholders across the public domain.

Chapter 15  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16  is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. An Overview of Drug Bioavailability
3.2. Need For Bioavailability Enhancement
3.3. Assessment of Drug Bioavailability
3.3.1. Key Considerations for Bioavailability Assessment Studies
3.3.1.1. Absolute Bioavailability
3.3.1.2. Relative Bioavailability
3.3.1.3. Single and Multiple Dose Studies
3.3.1.4. Studies in Healthy Subjects and Patients
3.3.2. Bioavailability Assessment Methods
3.4. Factors Affecting Bioavailability
3.4.1. Drug Related Factors
3.4.2. Patient Physiology Related Factors
3.5. Bioavailability Enhancement Technologies
3.5.1. Historical Overview
3.5.2. Physical Technologies for Bioavailability Enhancement
3.5.2.1. Solid Dispersion
3.5.2.1.1. Classification
3.5.2.1.2. Preparation Methodologies
3.5.2.1.2.1. Hot Melt Extrusion
3.5.2.1.2.2. Melting / Fusion Method
3.5.2.1.2.3. Solvent Evaporation
3.5.2.1.2.4. Spray-Dried Dispersion
3.5.2.1.2.5. Solid Dispersion: Other Techniques
3.5.2.2. Nanosuspension Technology
3.5.2.2.1. Top Down Approach
3.5.2.2.2. Bottom up Approach
3.5.3. Chemical Technologies for Bioavailability Enhancement
3.5.3.1. Lipid Based Formulations
3.5.3.2. Metal Based Drug Delivery Systems
3.5.3.3. Polymer Based Drug Delivery Systems
3.5.4. Biological Technologies
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Bioavailability Enhancement: List of Service Providers
4.2.1. Distribution by Company Portfolio
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Company Size
4.2.4. Distribution by Year of Establishment
4.2.5. Distribution by Bioavailability Enhancement Principle
4.2.6. Distribution by Bioavailability Enhancement Approach
4.2.6.1. Distribution by Lipid Based Approaches
4.2.6.2. Distribution by Size Reduction Approaches
4.2.6.3. Distribution by Solid Dispersion Approaches
4.2.6.4. Distribution by Other Approaches
4.2.7. Distribution by Dosage Form
4.2.8. Distribution by Route of Administration
4.2.9. Heat Map Analysis of Service Providers
4.2.10. Distribution by Leading Players
 
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Lonza
5.2.1. Company Overview
5.2.2. Financial Performance
5.2.3. Services Portfolio
5.2.4. Bioavailability Enhancement Services Portfolio
5.2.5. Recent Partnerships
5.2.6. Future Outlook
 
5.3. Catalent
5.3.1 Company Overview
5.3.2 Financial Performance
5.3.3 Services Portfolio
5.2.4. Bioavailability Enhancement Services Portfolio
5.2.5. Recent Partnerships
5.2.6. Future Outlook
 
5.4. Ascendia Pharmaceuticals
5.4.1. Company Overview
5.4.2. Services Portfolio
5.4.3. Bioavailability Enhancement Services Portfolio
5.4.4. Future Outlook
 
5.5. Particle Sciences (Acquired by Lubrizol)
5.4.1. Company Overview
5.4.2. Financial Performance
5.4.3. Services Portfolio
5.4.4. Bioavailability Enhancement Services Portfolio
5.4.5. Recent Partnerships
5.4.6. Future Outlook
 
5.6. Juniper Pharma Services
5.6.1. Company Overview
5.6.2. Financial Performance
5.6.3. Services Portfolio
5.6.4. Bioavailability Enhancement Services Portfolio
5.6.5. Recent Partnerships
5.6.6. Future Outlook
 
5.7. Phosphorex
5.7.1. Company Overview
5.7.2. Financial Performance
5.7.3. Services Portfolio
5.7.4. Bioavailability Enhancement Services Portfolio
5.7.5. Recent Partnerships
5.7.6. Future Outlook
 
5.8. Kuecept (Acquired by Aptuit / Evotec)
5.8.1. Company Overview
5.8.2. Financial Performance
5.8.3. Services Portfolio
5.8.4. Bioavailability Enhancement Services Portfolio
5.8.5. Recent Partnerships
5.8.6. Future Outlook
 
5.9. Creative Biolabs
5.9.1. Company Overview
5.9.2. Financial Performance
5.9.3. Services Portfolio
5.9.4. Bioavailability Enhancement Services Portfolio
5.9.5. Recent Partnerships
5.9.5. Future Outlook
 
5.10. WuXi AppTec
5.10.1. Company Overview
5.10.2. Financial Performance
5.10.3. Services Portfolio
5.10.4. Bioavailability Enhancement Services Portfolio
5.10.5. Recent Partnerships
5.10.6. Future Outlook
 
6. BENCHMARK ANALYSIS
6.1. Chapter Overview
6.2. Benchmark Analysis: Methodology
6.3. Benchmark Analysis: Peer Groups
6.3.1. Benchmark Analysis: North and South America, Peer Group I
6.3.2. Benchmark Analysis: North and South America, Peer Group II
6.3.3. Benchmark Analysis: North and South America, Peer Group III
6.3.4. Benchmark Analysis: Europe, Peer Group IV
6.3.5. Benchmark Analysis: Europe, Peer Group V
6.3.6. Benchmark Analysis: Asia-Pacific, Peer Group VI
6.3.7. Benchmark Analysis: Asia-Pacific, Peer Group VII
 
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Types of Partnerships
7.3. Bioavailability Enhancement: Analysis of Partnerships
7.3.1. Distribution by Year of Partnerships
7.3.2. Distribution by Type of Partnerships
7.3.3. Distribution by Most Active Companies
7.3.4. Distribution by Leading Acquirers
 
8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Bioavailability Enhancement: Analysis of Publications
8.2.1. Distribution by Year of Publications
8.2.2. Distribution by Key Journals
8.2.3. Emerging Areas: Word Clouds
8.2.4. Analysis be Key Approaches
8.2.4.1. Distribution by Number of Publications
8.2.4.2. Distribution by Year of Publications
8.2.4.3. Distribution by Growth Rate
8.2.4.4. Bubble Chart Analysis
8.2.5. Distribution by Leading Publications
 
9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Bioavailability Enhancement: Analysis of Patents
9.3.1. Distribution by Publication Year
9.3.2. Distribution by Geographical Location
9.3.3. Distribution by CPC Classification
9.3.4. Emerging Areas: Word Cloud
9.3.5. Patent Valuation
9.3.6 Leading Citations
 
10. CLINICAL TRIALS ANALYSIS
10.1. Chapter Overview
10.2. Guidelines to Conduct Bioavailability Studies
10.3. Clinical Trials Analysis
10.3.1. Research Methodology
10.3.2. Distribution by Study Start Date
10.3.3. Distribution by Study Design
10.3.4. Distribution by Phase
10.3.5. Distribution by Trial Status
10.3.6. Distributions of Types of Molecules by Phase of Development
10.3.7. Distribution by Leading Players
10.3.8. Study Focus: Word Cloud
 
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Bioavailability Enhancement Opportunities
11.3. Research Methodology
11.4. Demand Analysis: New Chemical Entities (NCEs)
11.5. Demand Analysis: Generics
 
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology
12.3. Overall Bioavailability Enhancement Market, 2020-2030
12.4. Bioavailability Enhancement Market: Distribution by BCS Classification
12.4.1. Bioavailability Enhancement Market by BCS II Drugs
12.4.2. Bioavailability Enhancement Market by BCS IV Drugs
12.5. Bioavailability Enhancement Market: Distribution by Type of Bioavailability Enhancement Approach
12.5.1. Bioavailability Enhancement Market by Lipid Based Approaches
12.5.2. Bioavailability Enhancement Market by Size Reduction Based Approaches
12.5.3. Bioavailability Enhancement Market by Solid Dispersion Based Approaches
12.5.4. Bioavailability Enhancement Market by Other Bioavailability Enhancement Approaches
12.6. Bioavailability Enhancement Market: Distribution by Geographical Location
12.6.1. Bioavailability Enhancement Market in the Americas (North America / South America)
12.6.2. Bioavailability Enhancement Market in Europe
12.6.3. Bioavailability Enhancement Market in Asia-Pacific
12.6.4. Bioavailability Enhancement Market in Rest of the World
 
13. CONCLUSION
13.1. Challenges Associated with Low Solubility and Permeability of Drugs Has Led to Increasing Demand for Bioavailability Enhancement
13.2. The Market is Characterized by The Presence of Several Established Players, As Well As Small and Mid-Sized Companies in Different Geographies
13.3. Size Reduction, Solid Dispersion and Lipid Based Methods are Offered by Several Technology / Service Providers; Players Offering Other Approaches are Also Emerging
13.4. The Field Has Witnessed Increasing Partnership Activity As Multiple Players are Collaborating for Expanding Capabilities
13.5. Ongoing Advances Have Led to Rapid Innovation and Increase in Patent Filling Activity
13.6. The Rising Number of BCS II and BCS IV Drugs and Increasing Adoption of Different Approaches for Enhancement of Drug Bioavailability is Likely to Foster the Long-Term Growth
 
14. TRANSCRIPTS OF PUBLIC DISCUSSIONS
14.1. Chapter Overview
14.2. David Vodak, Vice President of Chemistry, Bend Research
14.3. John K Tilloston, Pharmaceutical and Nutritional Technical Business Director, ABITEC
14.4. Kaspar van den Dries, Senior Director Formulation Sciences and Martin Piest, Senior Formulation Scientist, Patheon
14.5. Anonymous, MilliporeSigma Process Solutions
14.6. Brent Moody, Principal Scientist, Science and Technology, Catalent Pharma Solutions
14.7. Anonymous, Sancilio Pharmaceuticals
14.8. Frank Romanski, BASF Pharma Solutions
14.9. Karl Kolter, BASF Pharma Solutions
 
15. APPENDIX 1: TABULAR DATA
 
16. APPENDIX 2: LIST OF COMPANIES

List of Figures

Figure 3.1  Biopharmaceutical Classification System
Figure 3.2  Biopharmaceutical Classification System: Change in Trends 
Figure 3.3  Bioavailability Enhancement Technologies: Evolutionary Timeline
Figure 3.4  Different Designs to Study Drug Bioavailability
Figure 3.5  Single Dose Study to Evaluate Bioavailability
Figure 3.6  Multiple Dose Study to Evaluate Bioavailability
Figure 3.7  Bioavailability Assessment: Methodologies
Figure 3.8  Bioavailability Assessment: Factors Affecting Bioavailability
Figure 3.9  Solid Dispersion: Classifications
Figure 3.10  Solid Dispersion: Preparation Methodologies
Figure 3.11  Solid Dispersion: List of Drugs Prepared by Hot Melt Extrusion
Figure 3.12  Solid Dispersion: List of Drugs Prepared by Melting / Fusion
Figure 3.13  Solid Dispersion: List of Drugs Prepared by Solvent Evaporation
Figure 3.14  Solid Dispersion: List of Drugs Prepared by Spray-Dried Dispersion
Figure 3.15  Solid Dispersion: Melt Agglomeration Technique
Figure 3.16  Nanosuspension: Preparation Methodologies
Figure 3.17  Lipid Based Formulations: Classification
Figure 3.18  Biological Formulation Technologies
Figure 4.1  Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach and Geography
Figure 4.2  Bioavailability Enhancement Service Providers: Geographical Landscape 
Figure 4.3  Bioavailability Enhancement Service Providers: Distribution by Company Size
Figure 4.4  Bioavailability Enhancement Service Providers: Cumulative Distribution by Year of Establishment
Figure 4.5  Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Figure 4.6  Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Figure 4.7  Bioavailability Enhancement Service Providers: Distribution by Lipid Based  Approaches
Figure 4.8  Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Figure 4.9  Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Based Approaches
Figure 4.10  Bioavailability Enhancement Service Providers: Distribution by Other Formulation Approaches
Figure 4.11  Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Figure 4.12  Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Figure 4.13  Bioavailability Enhancement Service Providers: Heat Map Analysis by Dosage Form and Bioavailability Enhancement Approaches
Figure 4.14  Bioavailability Enhancement Service Providers: Leading Players
Figure 4.15  Bioavailability Enhancement Service Providers: Dosage Form Wise Global Distribution of Leading Players
Figure 5.1  Lonza: Annual Revenues, 2013-2017 (CHF Billion)
Figure 5.2  Lonza: Custom Contract Manufacturing Services
Figure 5.3  Lonza: Bioavailability Enhancement Services Portfolio
Figure 5.4  Catalent: Annual Revenues, 2013– 2017 (USD Billion)
Figure 5.5  Catalent: Revenues by Product Types, 2017 (USD Million)
Figure 5.6  Catalent: Services Portfolio
Figure 5.7  Catalent: Bioavailability Enhancement Services Portfolio 
Figure 5.8  Ascendia Pharmaceuticals: Services Portfolio
Figure 5.9  Ascendia Pharmaceuticals: Bioavailability Enhancement Services Portfolio
Figure 5.10  Particle Sciences: Services Portfolio
Figure 5.11  Particle Sciences: Bioavailability Enhancement Services Portfolio
Figure 5.12  Juniper Pharmaceuticals: Annual Revenues, 2013–2017 (USD Million)
Figure 5.13  Juniper Pharma Services: Services Portfolio
Figure 5.14  Juniper Pharma Services: Bioavailability Enhancement Services Portfolio
Figure 5.15  Phosphorex: Polymeric Nanoparticles Applications
Figure 5.16  Phosphorex: Bioavailability Enhancement Services Portfolio
Figure 5.17  Kuecept: Services Portfolio
Figure 5.18  Kuecept: Bioavailability Enhancement Services Portfolio
Figure 5.19  Creative Biolabs: Services Portfolio 
Figure 5.20  Creative Biolabs: Bioavailability Enhancement Services Portfolio
Figure 5.21  WuXi AppTec: Annual Revenues, 2010–Q3 2015 (USD Million)
Figure 5.22  WuXi AppTec: Services Portfolio
Figure 5.23  WuXi AppTec: Bioavailability Enhancement Services Portfolio
Figure 6.1  Benchmark Analysis: Distribution of Industry Players by Year of Establishment and Geographical Location
Figure 6.2  Benchmark Analysis: American Companies, Peer Group I
Figure 6.3  Benchmark Analysis: American Companies, Peer Group II
Figure 6.4  Benchmark Analysis: American Companies, Peer Group III
Figure 6.5  Benchmark Analysis: European Companies, Peer Group IV
Figure 6.6  Benchmark Analysis: European Companies, Peer Group V
Figure 6.7  Benchmark Analysis: European Companies, Peer Group VI
Figure 6.8  Benchmark Analysis: Asian Companies, Peer Group VII
Figure 6.9  Benchmark Analysis: Asian Companies, Peer Group VIII
Figure 7.1  Bioavailability Enhancement Partnerships: Cumulative Year-wise Trend
Figure 7.2  Bioavailability Enhancement Partnerships: Distribution by Type of Collaboration
Figure 7.3  Bioavailability Enhancement Partnerships: Yearly Distribution by Type of Collaboration
Figure 7.4  Bioavailability Enhancement Partnerships: Distribution by Most Active Players
Figure 7.5  Bioavailability Enhancement Partnerships: Distribution by Key Acquirers 
Figure 7.6  Bioavailability Enhancement Partnerships: Distribution by Key Acquirers and Year of Acquisitions 
Figure 8.1  Bioavailability Enhancement Publications: Cumulative Year-Wise Trend
Figure 8.2  Bioavailability Enhancement Publications: Top 15 Journals
Figure 8.3  Bioavailability Enhancement Publications: Emerging Areas
Figure 8.4  Bioavailability Enhancement Publications: Distribution of Approaches by Number of Publications
Figure 8.5  Bioavailability Enhancement Publications: Distribution of Approaches by Year of Publication
Figure 8.6  Bioavailability Enhancement Publications: Distribution of Approaches by CAGR (2008-2017)
Figure 8.7  Bioavailability Enhancement Publications: Technology Wise Bubble Chart Analysis
Figure 9.1  Bioavailability Enhancement Patents: Distribution by Type of Patent
Figure 9.2  Bioavailability Enhancement Patents: Distribution by Type of Technology
Figure 9.3  Bioavailability Enhancement Patents: Cumulative Distribution by Year and Bioavailability Enhancement Approach
Figure 9.4  Bioavailability Enhancement Patents: Distribution by Patent CAGR and Bioavailability Enhancement Approach 
Figure 9.5  Bioavailability Enhancement Patents: Distribution by Publication Year
Figure 9.6  Bioavailability Enhancement Patents: Year-wise Regional Distribution
Figure 9.7  Bioavailability Enhancement Patents: Cumulative Distribution by CPC Classification Symbol
Figure 9.8  Bioavailability Enhancement Patents: Emerging Areas
Figure 9.10  Bioavailability Enhancement Patents: Age of Patent
Figure 9.11  Bioavailability Enhancement Patents: Patent Valuation
Figure 9.12  Bioavailability Enhancement Patents: Geographical Patent Valuation
Figure 9.13  Bioavailability Enhancement Patents: Leading Players
Figure 10.1  Bioavailability Studies: Cumulative Year Wise Trend
Figure 10.2  Bioavailability Studies: Study Design
Figure 10.3  Bioavailability Studies: Clinical Trial Distribution
Figure 10.4  Bioavailability Studies: Trial Status Wise Distribution
Figure 10.5  Bioavailability Studies: Distribution of Molecules by Phase of Development
Figure 10.6  Bioavailability Studies: Leading Players
Figure 10.7  Bioavailability Studies: Study Focus
Figure 11.1  Demand Analysis: Enhanced Formulation Drug Approvals (2010-2015)
Figure 11.2  Demand Analysis: Likelihood of Approval
Figure 11.3  Demand Analysis: Distribution by Dosage Forms
Figure 11.4  Demand Analysis: Distribution of Types of Molecule by Phase of Development
Figure 11.5  Demand Analysis: Expected Phase wise BCS Distribution of Drugs (2030)
Figure 11.6  Demand Analysis: Expected Demand (NCEs)
Figure 11.7  Demand Analysis: Expected Demand (NCEs), Opportunity Segmentation by Technology (2025-2030)
Figure 11.8  Demand Analysis: Expected Demand (Generics)
Figure 11.9  Demand Analysis: Expected Demand (Generics), Opportunity Segmentation by Technology (2025-2030)
Figure 12.1  Bioavailability Enhancement Market: Cost of Bioavailability Enhancement, 
Figure 12.2  Bioavailability Enhancement Market: Trends in Out-Sourcing
Figure 12.3  Overall Bioavailability Enhancement Market, 2020-2030: Base Scenario (USD Billion)
Figure 12.4  Bioavailability Enhancement Market: Segmentation by BCS Classification, 2020-2030: Base Scenario (USD Billion)
Figure 12.5  Bioavailability Enhancement Market: Market Shares of Formulation Approaches, (2020, 2025, 2030)
Figure 12.6  Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2020-2030: Base Scenario (USD Billion)
Figure 12.7  Bioavailability Enhancement Market: Segmentation by Geographical Location, 2020-2030: Base Scenario (USD Billion)

List of Tables

Table 3.1  Solid Dispersion Method: List of Drugs
Table 3.2  Nanoparticles: List of Drugs
Table 3.3  Nanosuspensions: List of Drugs
Table 3.4  Liposome Based Formulations: List of Drugs
Table 3.5  Micelles Based Formulations: List of Drugs
Table 3.6  Micro-Emulsion Based Parenteral Formulations: List of Drugs
Table 3.7  Micro-Emulsion Based Oral Formulations: List of Drugs
Table 3.8  Lipid Based Oral Formulations: List of Drugs
Table 3.9  Metal Based Drug Delivery Approaches: List of Drugs
Table 3.10  Polymer Based Drug Delivery Approaches: List of Drugs
Table 3.11  Biological Formulation Technologies: List of Drugs
Table 4.1  Bioavailability Enhancement Service Providers: Information on Company Portfolio
Table 4.2  Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Approaches
Table 4.3  Bioavailability Enhancement Service Providers: Information on Lipid Based Approaches
Table 4.4  Bioavailability Enhancement Service Providers: Information on Size Reduction Approaches
Table 4.5  Bioavailability Enhancement Service Providers: Information on Solid Dispersion Based Approaches
Table 4.6  Bioavailability Enhancement Service Providers: Information on Other Approaches
Table 5.1  Lonza: Future Outlook
Table 5.2  Catalent: Future Outlook
Table 5.3  Catalent: List of Upcoming Conferences
Table 5.4  Ascendia Pharmaceuticals: Future Outlook
Table 5.5  Particle Sciences: Future Outlook
Table 5.6  Juniper Pharma Services: Future Outlook
Table 5.7  Phosphorex: Future Outlook
Table 5.8  Creative Biolabs: Future Outlook
Table 5.9  WuXi AppTec: Future Outlook
Table 6.1  Benchmark Analysis: Peer Groups
Table 7.1  Bioavailability Enhancement: Partnerships, 2013-2020 
Table 8.1  Bioavailability Enhancement: Leading Publications 
Table 9.1  Bioavailability Enhancement Patents: Most Popular CPC Symbols
Table 9.2  Bioavailability Enhancement Patents: List of Top CPC Classifications
Table 9.3  Bioavailability Enhancement Patents: List of Top Leading Patents
Table 10.1  Bioavailability Studies: Regulatory Guidelines and Methodologies
Table 14. 1  Technology Selection for Enhancing Bioavailability
Table 15.1  Bioavailability Enhancement Service Providers: Distribution by Type of Bioavailability Approach and Geography
Table 15.2  Bioavailability Enhancement Service Providers: Distribution by Company Size
Table 15.3  Bioavailability Enhancement Service Providers: Cumulative Distribution by Year of Establishment
Table 15.4  Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Table 15.5  Bioavailability Enhancement Service Providers: Distribution by the Type of Approach
Table 15.6  Bioavailability Enhancement Service Providers: Distribution by Lipid Based Approaches
Table 15.7  Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Table 15.8  Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Based Approaches
Table 15.9  Bioavailability Enhancement Service Providers: Distribution by Other Formulation Approaches
Table 15.10  Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Table 15.11  Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Table 15.12  Bioavailability Enhancement Service Providers: Heat Map Analysis by Dosage Form and Bioavailability Enhancement Approaches
Table 15.13  Lonza: Annual Revenues, 2013-2017 (CHF Billion)
Table 15.14  Catalent: Annual Revenues, 2013– 2017 (USD Billion)
Table 15.15  Catalent: Revenues by Product Types, 2017 (USD Million)
Table 15.16  Juniper Pharmaceuticals: Annual Revenues, 2013–2017 (USD Million)
Table 15.17  WuXi AppTec: Annual Revenues, 2010–Q3 2015 (USD Million)
Table 15.18  Benchmark Analysis: Distribution of Industry Players by Year of Establishment and Geographical Location
Table 15.19  Benchmark Analysis, Peer Group I: Distribution by Bioavailability Enhancement Principle
Table 15.20  Benchmark Analysis, Peer Group I: Distribution by Type of Bioavailability     Approach 
Table 15.21  Benchmark Analysis, Peer Group I: Distribution by Dosage Form
Table 15.22  Benchmark Analysis, Peer Group I: Distribution by Route of Administration
Table 15.23  Benchmark Analysis, Peer Group II: Distribution by Bioavailability Enhancement Principle
Table 15.24  Benchmark Analysis, Peer Group II: Distribution by Bioavailability Enhancement Approach 
Table 15.25  Benchmark Analysis, Peer Group II: Distribution by Dosage Form
Table 15.26  Benchmark Analysis, Peer Group II: Distribution by Route of Administration
Table 15.27  Benchmark Analysis, Peer Group III: Distribution by Bioavailability Enhancement Principle
Table 15.28  Benchmark Analysis, Peer Group III: Distribution by Bioavailability Enhancement Approach 
Table 15.29  Benchmark Analysis, Peer Group III: Distribution by Dosage Form
Table 15.30  Benchmark Analysis, Peer Group III: Distribution by Route of Administration
Table 15.31  Benchmark Analysis, Peer Group IV: Distribution by Bioavailability Enhancement Principle
Table 15.32  Benchmark Analysis, Peer Group IV: Distribution by Bioavailability Enhancement Approach
Table 15.33  Benchmark Analysis, Peer Group IV: Distribution by Dosage Form
Table 15.34  Benchmark Analysis, Peer Group IV: Distribution by Route of Administration
Table 15.35  Benchmark Analysis, Peer Group V: Distribution by Bioavailability Enhancement Approach
Table 15.36  Benchmark Analysis, Peer Group V: Distribution by Approach Type
Table 15.37  Benchmark Analysis, Peer Group V: Distribution by Dosage Form
Table 15.38  Benchmark Analysis, Peer Group V: Distribution by Route of Administration
Table 15.39  Benchmark Analysis, Peer Group VI: Distribution by Bioavailability Enhancement Principle
Table 15.40  Benchmark Analysis, Peer Group VI: Distribution by Bioavailability Enhancement Approach
Table 15.41  Benchmark Analysis, Peer Group VI: Distribution by Dosage Form
Table 15.42  Benchmark Analysis, Peer Group VI: Distribution by Route of Administration
Table 15.43  Benchmark Analysis, Peer Group VII: Bioavailability Enhancement Principle
Table 15.44  Benchmark Analysis, Peer Group VII: Distribution by Bioavailability Enhancement Approach
Table 15.45  Benchmark Analysis, Peer Group VII: Distribution by Dosage Form
Table 15.46  Benchmark Analysis, Peer Group VII: Distribution by Route of Administration
Table 15.47  Benchmark Analysis, Peer Group VIII: Distribution by Bioavailability Enhancement Principle
Table 15.48  Benchmark Analysis, Peer Group VIII: Distribution by Bioavailability Enhancement Approach 
Table 15.49  Benchmark Analysis, Peer Group VIII: Distribution by Dosage Form
Table 15.50  Benchmark Analysis, Peer Group VIII: Distribution by Route of Administration
Table 15.51  Bioavailability Enhancement Partnerships: Cumulative Year-wise Trend
Table 15.52  Bioavailability Enhancement Partnerships: Distribution by Type of Collaboration
Table 15.53  Bioavailability Enhancement Partnerships: Distribution by Most Active Players
Table 15.54  Bioavailability Enhancement Partnerships: Distribution by Leading Acquirers
Table 15.55  Bioavailability Enhancement Publications: Cumulative Year-Wise Trend
Table 15.56  Bioavailability Enhancement Publications: Top 15 Journals
Table 15.57  Bioavailability Enhancement Publications: Distribution of Approaches by Number of Publications
Table 15.58  Bioavailability Enhancement Publications: Year-Wise Technology Distribution
Table 15.59  Bioavailability Enhancement Publications: Distribution of Approaches by CAGR (2008-2017)
Table 15.60  Bioavailability Enhancement Publications: Bubble Analysis
Table 15.61  Bioavailability Enhancement Publications: Distributions of Top Publications by Technology
Table 15.62  Bioavailability Enhancement Patents: Distribution by Type of Patent
Table 15.63  Bioavailability Enhancement Patents: Distribution by Type of Approach
Table 15.64  Bioavailability Enhancement Patents: Cumulative Distribution by Publication Years for Bioavailability Enhancement Approaches
Table 15.65  Bioavailability Enhancement Patents: Distribution by Bioavailability Enhancement Approach and Patent CAGR
Table 15.66  Bioavailability Enhancement Patents: Distribution by Publication Year
Table 15.67  Bioavailability Enhancement Patents: Year-Wise Regional Distribution
Table 15.68  Bioavailability Enhancement Patents: Age of Patent
Table 15.69  Bioavailability Enhancement Patents: Patent Valuation
Table 15.70  Bioavailability Studies: Cumulative Year Wise Trend
Table 15.71  Bioavailability Studies: Intervention of Study
Table 15.72  Bioavailability Studies: Purpose of Study
Table 15.73  Bioavailability Studies: Allocation of Study
Table 15.74  Bioavailability Studies: Masking of Study
Table 15.75  Bioavailability Studies: Clinical Trials Distribution
Table 15.76  Bioavailability Studies: Trial Status Wise Distribution
Table 15.77  Bioavailability Studies: Distribution of Types of Molecule by Phase of Development
Table 15.78  Bioavailability Studies: Leading Players
Table 15.79  Demand Analysis: Enhanced Formulation Drug Approvals (2010-2015)
Table 15.80  Demand Analysis: Likelihood of Approval
Table 15.81  Demand Analysis: Distribution by Dosage Forms
Table 15.82  Demand Analysis: Phase wise BCS Distribution of Drugs (2020)
Table 15.83  Demand Analysis: Expected Phase wise BCS Distribution of Drugs (2030)
Table 15.84  Demand Analysis: Expected Demand (NCEs)
Table 15.85  Demand Analysis: Expected Demand (NCEs), Opportunity Segmentation by Technology (2025-2030)
Table 15.86  Demand Analysis: BCS for Generic Drugs, 2013 Scenario
Table 15.87  Demand Analysis: BCS for Generic Drugs, 2020 Scenario
Table 15.88  Demand Analysis: BCS for Generic Drugs, 2030 Scenario
Table 15.89  Demand Analysis: Expected Demand (Generic Drugs)
Table 15.90  Bioavailability Enhancement Market: Trends in Bioavailability Enhancement Cost, 2020-2030 (USD Million)
Table 15.91  Bioavailability Enhancement Market: Drugs Adopting Out-Licensing Approach for Bioavailability Enhancement
Table 15.92  Overall Bioavailability Enhancement Market, 2020-2030: Conservative Scenario (USD Billion)
Table 15.93  Overall Bioavailability Enhancement Market, 2020-2030: Base Scenario (USD Billion)
Table 15.94  Overall Bioavailability Enhancement Market, 2020-2030: Optimistic Scenario (USD Billion)
Table 15.95  Bioavailability Enhancement Market: Segmentation by BCS Classification, 2020-2030: Conservative Scenario (USD Billion)
Table 15.96  Bioavailability Enhancement Market: Segmentation by BCS Classification, 2020-2030: Base Scenario (USD Billion)
Table 15.97  Bioavailability Enhancement Market: Segmentation by BCS Classification, 2020-2030: Optimistic Scenario (USD Billion)
Table 15.98  Bioavailability Enhancement Market: Market Shares of Formulation Approaches, (2020, 2025, 2030)
Table 15.99  Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2020-2030: Conservative Scenario (USD Billion)
Table 15.100  Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2020-2030: Base Scenario (USD Billion)
Table 15.101  Bioavailability Enhancement Market: Segmentation by Formulation Approaches, 2020-2030: Optimistic Scenario (USD Billion)
Table 15.102  Bioavailability Enhancement Market: Segmentation by Geographical Location, 2020-2030: Conservative Scenario (USD Billion)
Table 15.103  Bioavailability Enhancement Market: Segmentation by Geographical Location, 2020-2030: Base Scenario (USD Billion)
Table 15.104  Bioavailability Enhancement Market: Segmentation by Geographical Location, 2020-2030: Optimistic Scenario (USD Billion)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. Abbott 
  2. AbbVie Contract Manufacturing
  3. ABITEC
  4. Accu-Break Pharmaceuticals
  5. Aché Laboratórios Farmacêuticos
  6. Acorn Biomedical
  7. Actavis
  8. Adare Pharmaceuticals
  9. Admas Pharmaceuticals
  10. Aegis Therapeutics
  11. Aesica
  12. Agere Pharmaceuticals
  13. Aizant Drug Research Solutions
  14. Ajinomoto
  15. Alcami
  16. Alexion Pharmaceuticals
  17. Alkermes
  18. Allergan
  19. Alliance Contract Pharma
  20. Almac Group
  21. Althea Technologies
  22. Altum Pharmaceuticals
  23. Altus Formulation
  24. Amatsigroup
  25. AMRI
  26. Applied Manufacturing Science
  27. Aquestive Therapeutics
  28. Arbro Pharmaceuticals
  29. Arbutus Biopharma
  30. Ardena Group
  31. Ascendia Pharmaceuticals
  32. Ashland
  33. Athenex
  34. Avara Pharmaceutical Services
  35. Avro Pharma
  36. Avomeen Analytical Services
  37. BASF
  38. Baxter International
  39. BEC Chemicals
  40. Bend Research
  41. BioConnection
  42. BioDuro
  43. Bionpharma
  44. Bio-serv
  45. Bridgepoint Development Capital
  46. Calando Pharmaceuticals
  47. Calvert Laboratories
  48. Camurus
  49. Capsugel
  50. Catalent
  51. CEPiA Sanofi
  52. Cerenis Therapeutics
  53. ChemConnection
  54. Chiasma Pharma
  55. Co-Formulate
  56. Colorcon
  57. Continuous Technologies International
  58. Corazon
  59. COREALIS Pharma
  60. CoreRx
  61. Creative Biolabs
  62. CritiTech
  63. Croda International
  64. Crystal Pharmatech
  65. Crystallics
  66. CrystecPharma
  67. CuriRx
  68. Cyclolab
  69. Cyndea Pharma
  70. Cytec
  71. Dalton Pharma Services
  72. Dauntless Pharmaceuticals
  73. DisperSol Technologies
  74. Dow Pharma Solutions
  75. Eagle Pharmaceuticals
  76. École Polytechnique Fédérale de Lausanne
  77. Emisphere Technologies
  78. Emmerson Resources
  79. Entera Bio
  80. Enteris BioPharma
  81. Evonik Health Care
  82. Evotec
  83. ExxPharma Therapeutics
  84. Ferring Pharmaceuticals
  85. Forest Laboratories
  86. Formac Pharmaceuticals
  87. Formex
  88. Foster Delivery Science
  89. Friulchem
  90. Fuji Chemical Industries
  91. Gattefossé
  92. Generex Biotechnology
  93. GenPlus
  94. Glatt Integrated Process Solutions
  95. Glenmark Pharmaceuticals
  96. GP Pharm
  97. GVK Biosciences
  98. Halo Pharma
  99. Harvard University
  100. Helix BioPharma
  101. Hovione
  102. IACTA Pharmaceuticals
  103. iCeutica
  104. IMCD 
  105. Indena
  106. Industrias Biocontrolled
  107. Instillo Group
  108. Intas Pharmaceuticals
  109. Intec Pharma
  110. Jamia Hamdard University
  111. Jetpharma
  112. Jina Pharmaceuticals
  113. Juniper Pharma Services
  114. Keystone Nano
  115. Kinex Pharmaceuticals
  116. Kuecept
  117. LATITUDE Pharmaceuticals
  118. leon-nanodrugs
  119. Lexaria Bioscience
  120. Ligand Pharmaceuticals
  121. Lipomize
  122. Lonza
  123. Losan Pharma
  124. Lubrizol
  125. Lypro Biosciences
  126. Marinus Pharmaceuticals
  127. Matinas BioPharma
  128. Merrion Pharmaceuticals
  129. Metrics Contract Services
  130. MicroChem
  131. Microfine Pharma
  132. Micro-Macinazione
  133. Micro-Sphere
  134. Midas Pharma
  135. MIKA PHARMACEUTICALS
  136. Molecular Profiles
  137. Monash University
  138. Mutchler
  139. Nanocopoeia
  140. Nanomaterials
  141. Nanomerics
  142. Nanosphere Health Sciences
  143. Natco Pharma
  144. Nemus Bioscience
  145. NETZSCH Premier Technologies 
  146. NeutriSci Internatinal
  147. New York Center for Nanomedicine Research
  148. Nippon Soda 
  149. Nisso America
  150. NMT Pharmaceuticals
  151. Nordic Bioscience
  152. Novaliq
  153. Novartis Pharmaceuticals
  154. Novo Nordisk
  155. Novozymes 
  156. Nuformix Technologies
  157. Oasmia Pharmaceutical
  158. Okklo Life Sciences
  159. Opiant Pharmaceuticals
  160. Pacira Pharmaceuticals
  161. Particle Sciences
  162. Patheon
  163. Phares Drug Delivery
  164. Pharmaceutics International
  165. PharmaIN
  166. PharmaSol
  167. Pharmatek Laboratories
  168. Pharmavize
  169. Phasex
  170. Phivida
  171. Phosphorex
  172. Pivot Pharmaceuticals
  173. PixarBio
  174. Planet Science
  175. PolyPeptide Group
  176. Porton Pharma Solutions
  177. PowderSize
  178. Prinova Group
  179. PriviLS
  180. ProCepT
  181. ProJect Pharmaceutics
  182. ProMed Pharma
  183. Pulmatrix
  184. PureTech Health
  185. Quay Pharma Services
  186. Quotient Sciences
  187. Rani Therapeutics
  188. Rhythm Pharmaceuticals
  189. Rondol Industrie
  190. Rottendorf Pharma
  191. Rubicon Research
  192. Samyang Biopharmaceuticals
  193. Sancilio Pharmaceuticals Company
  194. SARA Pharm Solutions
  195. SciTech Development
  196. SEPS Pharma
  197. Shin-Etsu Chemical
  198. Shionogi
  199. Siegfried Holding
  200. Singota Solutions
  201. SiTec PharmaBio
  202. SkyePharma
  203. SolMic Research
  204. SoluBest
  205. Solvias
  206. STA Pharmaceutical
  207. Stanipharm
  208. Supernus Pharmaceuticals
  209. Tapemark
  210. Tergus Pharma
  211. Transgene Biotek
  212. Univar
  213. UPM Pharmaceuticals
  214. Upperton Pharma Solutions
  215. Variant Pharmaceuticals
  216. Vectura
  217. Veloxis Pharmaceuticals
  218. Vesifact
  219. Vitasome
  220. VxP Pharma
  221. W. R. Grace
  222. WuXi AppTec
  223. Xcelience
  224. Xedev
  225. XenoGesis
  226. Xi'an Hongchang Pharmaceuticals
  227. Xisle Pharma Ventures 
  228. Yale University
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com